Skip to content
Trial Eligibility
Menu

Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease

NCT07950878

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • ARPKD

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
0 months to 25 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Children's Hospital of Philadelphia
Last updated on ClinicalTrials.gov
November 20, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Pennsylvania · 1

  • Children's Hospital of Philadelphia · Philadelphia, PA

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.